Canada markets closed
  • S&P/TSX

    -144.22 (-0.63%)
  • S&P 500

    -78.93 (-1.39%)
  • DOW

    +243.60 (+0.59%)

    +0.0002 (+0.02%)

    +0.66 (+0.80%)
  • Bitcoin CAD

    -1,955.83 (-2.17%)
  • CMC Crypto 200

    -4.97 (-0.37%)

    +4.00 (+0.16%)
  • RUSSELL 2000

    -24.00 (-1.06%)
  • 10-Yr Bond

    -0.0210 (-0.50%)
  • NASDAQ futures

    +66.50 (+0.33%)

    +1.29 (+9.78%)
  • FTSE

    +22.56 (+0.28%)
  • NIKKEI 225

    -778.59 (-1.89%)

    +0.0001 (+0.01%)

Microbix Presenting at Florida Capital Event Conference

Microbix Biosystems Inc.
Microbix Biosystems Inc.

Meetings with Growth-Oriented Investors, November 17 to 19, 2023

MISSISSAUGA, Ontario, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be presenting to investors at the Florida Capital Event Conference, organized by Capital Event Management Ltd. and being hosted at the JW Marriott Turnberry, in Aventura, Florida, November 17 to 19, 2023.

Microbix’s CEO & President, Cameron Groome, will undertake a series of 18 one-on-one meetings with growth company investors during the formal portion of the conference. The presentation slides to which he will be speaking will be posted to the Microbix website at, along with other business information and financial disclosures.


Shareholders may also join a webinar reviewing announced progress on Kinlytic® and overall operations. This webinar is being hosted by Adelaide Capital at 10:00 AM ET on Friday, November 17, 2023. Participants can register here:

The webinar will also be live-streamed and a replay will be posted on Adelaide Capital’s YouTube Channel here:

About Microbix Biosystems
Microbix creates proprietary biological products for human health, with over 100 skilled employees and annualized sales targeting C$ 2.0 million per month. It makes a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™ IVD or RUO test-controls) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical lab and point-of-care diagnostic workflows. Microbix antigens enable the antibody tests of approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 and 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides CE marked products.

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic® urokinase, a biologic drug used to dissolve blood clots, and viral transport medium (DxTM™) used to stabilize patient samples for lab-based molecular diagnostic testing. Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada.

About Capital Event Management Ltd. and the Event
Capital Event Management Ltd. produces multiple investor events each year, across North America, on Bermuda, and in the Bahamas. Attendees include leading public and private companies, and a range of investors consisting of investment advisors, fund managers, and high net worth investors. Capital Event’s unique event formats aim to allow principals to establish new and lasting relationships that lead to financings, open market support, and increased awareness within the investment community. Further information about the Florida event is available at

Forward-Looking Information
This news release includes “forward-looking information,” as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, discussion of Capital Event Management Ltd. and its conferences, Microbix’s business and business results, goals or outlook, risks associated with financial results and stability, development projects such as those referenced in its corporate presentation or verbal comments, sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity and timeliness of delivery), foreign currency and exchange rates, maintaining profitability and adequate working capital, or raising further capital on acceptable terms or at all, and other similar statements concerning anticipated future events, conditions or results that are not historical facts. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward looking information is inherently uncertain, and that actual performance may be affected by many material factors, some of which are beyond the Company’s control. Accordingly, actual future events, conditions, and results may differ materially from the estimates, beliefs, intentions, and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent the Company’s judgement as of the date of this new release, and the Company is under no obligation to update or alter any forward-looking information.

Please visit or for recent Microbix news and filings.

For further information, please contact Microbix at:

Cameron Groome, CEO
(905) 361-8910

Jim Currie,
(905) 361-8910

Deborah Honig,
Investor Relations
Adelaide Capital Markets
(647) 203-8793

Copyright © 2023 Microbix Biosystems Inc.
Microbix®, DxTM™, Kinlytic®, and QAPs™ are trademarks of Microbix Biosystems Inc.